Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Exalenz Bioscience to Participate in Upcoming Investor Conferences

Posted on: 09 Mar 18

MODI’IN, Israel and MANASQUAN, N.J., March 09, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced that management will be participating in the following healthcare investor conferences:

  • Barclays Global Healthcare Conference – Loews Miami Beach Hotel in Florida (March 13-15, 2018).  Members of the management team will participate in one-on-one meetings with investors on Wednesday and Thursday, March 14-15.
  • H.C. Wainwright & Co. 2nd Annual NASH Investor Conference – St. Regis Hotel in New York (March 19, 2018).  Chief Executive Officer Raffi Werner will deliver a company presentation at 2:00pm ET and members of the management team will participate in one-on-one meetings with investors.
  • Oppenheimer 28th Annual Healthcare Conference — The Westin New York Grand Central (March 20-21, 2018). Mr. Werner will deliver a company presentation at 4:30pm ET on Tuesday, March 20 and members of the management team will participate in one-on-one meetings with investors that day.

About Exalenz Bioscience
Exalenz Bioscience develops and markets diagnostic tests and monitoring systems that use the breath to diagnose and help manage gastrointestinal and liver conditions. The company’s flagship BreathID® Hp offers the most efficient and accurate test for detection of H. pylori bacteria, associated with various illnesses including gastric cancer, and is already in use in over 400 U.S. medical centers and major labs across the country. The BreathID 13C-methacetin breath test (MBT) is a sensitive, noninvasive, point of care tool that measures the microsomal function of the liver. Exalenz holds regulatory approvals in Europe, the United States, China and Israel for H. pylori detection and is currently evaluating additional applications of the BreathID platform, including MBT in the detection of CSPH in patients with NASH. Additional information is available at

Contact Information

Investor Relations
David Carey

Glenn Silver



Last updated on: 12/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.